Admedus (ASX: AHZ) today announced the appointment of Genpharm as its exclusive partner for CARDIOCEL in the Middle East and North Africa region.
Genpharm is a Dubai-based specialty marketing and sales healthcare company focussed on market access in the Middle East and North Africa, one of the fastest growing healthcare regions globally.
The region's eight largest countries have a combined population of over 120 million people.
“Admedus is highly strategic in the selection and appointment of specialist distributors in regions where we do not have a direct sales force. This forms an important part of our global launch strategy for CARDIOCEL,” said Admedus CEO Mr Lee Rodne.
“Genpharm has a strong reputation and presence in the region and we look forward to broadening CARDIOCEL’s availability globally,” he said.
According to Mr Karim Smaira, Genpharm managing partner, “We feel excited to partner with Admedus in bringing CARDIOCEL to the MENA region for the repair of heart defects in both children and adult patients. We are both committed to improving the quality of life for these patients.”
The expansion of CARDIOCEL into the MENA region grows the number of centres using the product globally. There are currently 31 centres in Europe and 31 centres in the USA, and recent approvals for use in Canada and Hong Kong.
CARDIOCEL is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects. It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs.